3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Ovarian Neoplasms
12
Small Cell Lung Carcinoma
11
Fallopian Tube Neoplasms
9
Neuroblastoma
6
Neoplasm Metastasis
3
Lung Neoplasms
3
Ganglioneuroblastoma
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Sarcoma, Ewing
2
Rhabdoid Tumor
2
Recurrence
2
Leukemia, Myeloid, Acute
2
Glioma
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Thrombocythemia, Essential
1
SCLC
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pleuropulmonary blastoma
1
Peritoneal Neoplasms
1
Pediatric Brain Tumor
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Lymphoma, Follicular
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
sacituzumab govitecan
1
amrubicin
1
Topotecan
1
PM 01183
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
×
Topotecan
×
90 days
×
Clear all
NCT06801834
2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3
Recruiting
695 enrolled